Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Egan, AM; Vellinga, A; Harreiter, J; Simmons, D; Desoye, G; Corcoy, R; Adelantado, JM; Devlieger, R; Van Assche, A; Galjaard, S; Damm, P; Mathiesen, ER; Jensen, DM; Andersen, L; Lapolla, A; Dalfra, MG; Bertolotto, A; Mantaj, U; Wender-Ozegowska, E; Zawiejska, A; Hill, D; Jelsma, JGM; Snoek, FJ; Worda, C; Bancher-Todesca, D; van Poppel, MNM; Kautzky-Willer, A; Dunne, FP.
Epidemiology of gestational diabetes mellitus according to IADPSG/WHO 2013 criteria among obese pregnant women in Europe
DIABETOLOGIA. 2017; 60(10): 1913-1921.
Web of Science FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Desoye Gernot
Gendermonitor:
Altmetrics:

Abstract:
Aims/hypothesis Accurate prevalence estimates for gestational diabetes mellitus (GDM) among pregnant women in Europe are lacking owing to the use of a multitude of diagnostic criteria and screening strategies in both high-risk women and the general pregnant population. Our aims were to report important risk factors for GDM development and calculate the prevalence of GDMin a cohort of women withBMI >= 29 kg/m(2) across 11 centres in Europe using the International Association of the Diabetes and Pregnancy Study Groups (IADPSG)/WHO 2013 diagnostic criteria. Methods Pregnant women (n = 1023, 86.3% European ethnicity) with a BMI = 29.0 kg/m(2) enrolled into the Vitamin D and Lifestyle Intervention for GDM Prevention (DALI) pilot, lifestyle and vitamin D studies of this pan-European multicentre trial, attended for an OGTT during pregnancy. Demographic, anthropometric and metabolic data were collected at enrolment and throughout pregnancy. GDM was diagnosed using IADPSG/WHO 2013 criteria. GDM treatment followed local policies. Results The number of women recruited per country ranged from 80 to 217, and the dropout rate was 7.1%. Overall, 39% of women developed GDM during pregnancy, with no significant differences in prevalence across countries. The prevalence of GDM was high (24%; 242/1023) in early pregnancy. Despite interventions used in the DALI study, a further 14% (94/672) had developed GDM when tested at mid gestation (24-28 weeks) and 13% (59/476) of the remaining cohort at late gestation (35-37 weeks). Demographics and lifestyle factors were similar at baseline between women with GDM and those who maintained normal glucose tolerance. Previous GDM (16.5% vs 7.9%, p = 0.002), congenital malformations (6.4% vs 3.3%, p = 0.045) and a baby with macrosomia (31.4% vs 17.9%, p = 0.001) were reported more frequently in those who developed GDM. Significant anthropometric and metabolic differences were already present in early pregnancy between women who developed GDM and those who did not. Conclusions/interpretation The prevalence of GDM diagnosed by the IADPSG/WHO 2013 GDM criteria in European pregnant women with a BMI >= 29.0 kg/m(2) is substantial, and poses a significant health burden to these pregnancies and to the future health of the mother and her offspring. Uniform criteria for GDM diagnosis, supported by robust evidence for the benefits of treatment, are urgently needed to guide modern GDM screening and treatment strategies.

Find related publications in this database (Keywords)
Clinical diabetes
Clinical science and care
Epidemiology
Healthcare delivery
Pregnancy
Weight regulation and obesity
© Meduni Graz Impressum